316 related articles for article (PubMed ID: 11743742)
1. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.
Achira M; Suzuki H; Ito K; Sugiyama Y
AAPS PharmSci; 1999; 1(4):E18. PubMed ID: 11741214
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Pharm Res; 2000 Oct; 17(10):1189-97. PubMed ID: 11145223
[TBL] [Abstract][Full Text] [Related]
6. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4.
Bhardwaj RK; Glaeser H; Becquemont L; Klotz U; Gupta SK; Fromm MF
J Pharmacol Exp Ther; 2002 Aug; 302(2):645-50. PubMed ID: 12130727
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Katoh M; Nakajima M; Yamazaki H; Yokoi T
Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
[TBL] [Abstract][Full Text] [Related]
8. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4.
Ohnishi A; Matsuo H; Yamada S; Takanaga H; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Br J Pharmacol; 2000 Jul; 130(6):1369-77. PubMed ID: 10903978
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
10. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
Brandes LJ; Queen GM; LaBella FS
Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Eagling VA; Profit L; Back DJ
Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
[TBL] [Abstract][Full Text] [Related]
13. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein.
Edwards DJ; Fitzsimmons ME; Schuetz EG; Yasuda K; Ducharme MP; Warbasse LH; Woster PM; Schuetz JD; Watkins P
Clin Pharmacol Ther; 1999 Mar; 65(3):237-44. PubMed ID: 10096255
[TBL] [Abstract][Full Text] [Related]
14. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4.
Takanaga H; Ohnishi A; Yamada S; Matsuo H; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
J Pharmacol Exp Ther; 2000 Apr; 293(1):230-6. PubMed ID: 10734174
[TBL] [Abstract][Full Text] [Related]
15. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Dresser GK; Spence JD; Bailey DG
Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
[TBL] [Abstract][Full Text] [Related]
17. Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives.
Shou M; Mei Q; Ettore MW; Dai R; Baillie TA; Rushmore TH
Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):845-53. PubMed ID: 10359672
[TBL] [Abstract][Full Text] [Related]
18. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
19. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
20. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.
Kenworthy KE; Bloomer JC; Clarke SE; Houston JB
Br J Clin Pharmacol; 1999 Nov; 48(5):716-27. PubMed ID: 10594474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]